Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

Autor: Vivian Y, Shi, Tina, Bhutani, Luz, Fonacier, Mette, Deleuran, Stephen, Shumack, Hernan, Valdez, Fan, Zhang, Gary L, Chan, Michael C, Cameron, Natalie C, Yin

Publikováno v: Shi, V Y, Bhutani, T, Fonacier, L, Deleuran, M, Shumack, S, Valdez, H, Zhang, F, Chan, G L, Cameron, M C & Yin, N C 2022, ' Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND) ', Journal of the American Academy of Dermatology, vol. 87, no. 2, pp. 351-358 . https://doi.org/10.1016/j.jaad.2022.04.009

BACKGROUND: Abrocitinib efficacy by prior dupilumab response status in patients with moderate-to-severe atopic dermatitis (AD) has not previously been assessed in phase 3 studies.OBJECTIVE: Examine efficacy and safety of abrocitinib among patients wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9a7a61a7bb21623cbeb8dbaf42cf563
https://doi.org/10.1016/j.jaad.2022.04.009

Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long-Term Extension Study

Autor: Vivian Shi, Tina Bhutani, Mette Deleuran, Luz Fonacier, Stephen Shumack, Fan Zhang, Michael C. Cameron, Gary L. Chan, Hernan Valdez, Natalie Yin

Publikováno v: SKIN The Journal of Cutaneous Medicine. 7:s153

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f111d7b91ec47d3f732dc9260f5bb5fd
https://doi.org/10.25251/skin.7.supp.153

Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years

Autor: Eric L. Simpson, Johnathan Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Haiyun Fan, Saleem A. Farooqui, Gary L. Chan, Justine Alderfer, William Romero, Susan Johnson

Publikováno v: SKIN The Journal of Cutaneous Medicine. 7:s150

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::288954ee48ceea040606ee6aa5aeeb7c
https://doi.org/10.25251/skin.7.supp.150

Impact de l’abrocitinib sur la réponse vaccinale chez les adolescents présentant une dermatite atopique modérée à sévère recevant les vaccins courants contre la diphtérie, la coqueluche et le tétanos dans l’étude de phase III JADE TEEN

Autor: Michael J. Cork, Gary L. Chan, Carsten Flohr, Lawrence F. Eichenfield, Claire Feeney, Fan Zhang, Ricardo Rojo, Hernan Valdez, Sébastien Barbarot, Christine Bangert

Publikováno v: Annales de Dermatologie et de Vénéréologie - FMC. 1:A354-A355

Introduction L’abrocitinib, un inhibiteur de JAK-1 par voie orale, ameliore de maniere significative les signes et symptomes de la dermatite atopique chez les adolescents et les adultes presentant une DA moderee a severe. L’impact de l’abrociti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8af7e217c84fd7e1ed5d8f6ec1e37f34
https://doi.org/10.1016/j.fander.2021.09.427

Relative performance of specific and nonspecific fluorescence polarization immunoassay for cyclosporine in transplant patients

Autor: William W. Lefor, Lawrence Kahana, Edward Spoto, S. Weinstein, Dana L. Shires, Gary L. Chan

Publikováno v: Therapeutic drug monitoring. 14(1)

The analytical performance of specific and nonspecific fluorescence polarization immunoassays (FPIAs, Abbott Laboratories) for cyclosporine was compared. Both specific and nonspecific FPIAs demonstrated excellent between-run coefficients of variation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::593817f4b0026e2a8689240f63933209
https://pubmed.ncbi.nlm.nih.gov/1546388